Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Fig. 1

Representative flow cytometric analysis of a Ph+ALL patient sample sorted according to the distribution of CD34, CD38 and CD58 expression. In the viable bone marrow mononuclear cells (BMMNCs) of a de novo Ph+ALL patient, the LPCs (CD34+CD38CD58) and other cells (CD34+CD38CD58+, CD34+CD38+CD58 and CD34+CD38+CD58+) fractions were sorted simultaneously

Back to article page